A carregar...
Rituximab therapy of recalcitrant bullous dermatoses
BACKGROUND: Rituximab is a monoclonal antibody directed against CD20 cell surface antigen of B-lymphocytes. Recent studies have demonstrated effectivity in recalcitrant bullous pemphigoid. The data available on other types of autoimmune bullous disease is more scant. MAIN OBSERVATION: Here we report...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Specjalisci Dermatolodzy
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3157775/ https://ncbi.nlm.nih.gov/pubmed/21886702 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3315/jdcr.2008.1007 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|